Análise da efetividade e segurança nos novos agentes antivirais de ação direta contra o vírus da Hepatite C no estado de Sergipe

• Autor(a) principal: Nascimento, Isis Alessandra Oliveira
• Data de Publicação: 2017
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: https://ri.ufs.br/handle/riufs/6740
• topic: Farmácia; Ensino de famacologia; Hepatite C; Tratamento da hepatite; Drugstore; Teaching of famacology; Hepatitis C; Treatment of hepatitis; CIENCIAS BIOLOGICAS::FARMACOLOGIA::FARMACOLOGIA CLINICA

Chronic HCV hepatitis affects about 180 million people worldwide. It is estimated that 3% of the world's population is infected with the virus and that between 60% and 70% of the patients will develop chronic liver disease, requiring specialized and highly complex health care. The objective of this study is to evaluate the prognosis of patients infected with hepatitis C who used the new clinical protocol of the Ministry of Health established in 2015 in a reference center in the state of Sergipe, in which we analyzed the clinical evolution, probability of relapse and possible adverse effects. Information regarding age, gender, virus genotype, adverse drug reactions, and Polymerase Chain Reaction (PCR) at week 4, end of treatment and 12 weeks after the end of treatment to confirm Sustained Virologic Response (SVR) were collected in medical records. A total of 81 patients were evaluated, of which 53 were men (65.5%) and 28 were women (34.5%), with ages between 20 and 79 years. The genotypes of hepatitis C virus found among study participants were 1, 2 and 3, respectively, in 57 (70.4%), 2 (2.5%) and 20 (24.6%) patients. Another 2 patients from this group (2.5%) had a double genotype (1a + 1b and 1a + 2). The 4th week PCR was undetectable in 41 (51.3%) patients and was detectable in 36 (46.7%) of the 77 patients who delivered the test result in that period. At the end of treatment, the viral load was undetectable in 50 (91%) of the patients and 5 (9%) were detectable in the 55 patients who underwent the test so far. RVS was observed in 34 (94.2%). The main adverse reactions developed during treatment were fatigue, anemia, headache and nausea. The results of the study demonstrated a higher value of undetected viral load at the end of treatment (SVR> 90%), better effectiveness and lower incidence of adverse reactions to hepatitis C virus.